Kronos Bio (KRON) Q4 2024 earnings summary

Executive summary

• Reported Q4 2024 net loss of $25.8 million ($0.43/share) and full-year net loss of $86.1 million ($1.43/share), both including non-cash stock-based compensation expenses.

• Initiated a process in November 2024 to evaluate strategic alternatives, including potential mergers, acquisitions, or asset sales.

Financial highlights

• Q4 2024 revenue was $2.3 million, nearly flat year-over-year; full-year 2024 revenue was $9.8 million, up from $6.3 million in 2023.

• Research and development expenses declined to $8.4 million in Q4 2024 from $18.7 million in Q4 2023; full-year R&D expenses fell to $48.7 million from $84.5 million year-over-year.

• General and administrative expenses decreased to $4.9 million in Q4 2024 from $9.2 million in Q4 2023; full-year G&A expenses dropped to $24.6 million from $39.0 million year-over-year.

• Impairment and restructuring charges rose sharply to $16.1 million in Q4 2024 (vs. $2.0 million prior year); full-year charges were $29.5 million, up from $4.9 million in 2023.

• Cash, cash equivalents, and investments totaled $112.4 million as of December 31, 2024, down from $124.4 million at year-end 2023.

Outlook and guidance

• Ongoing evaluation of strategic alternatives may result in significant changes to operations or ownership structure.